NCT01694459

Brief Summary

International guidelines support the use of a full-dose heparin (anticoagulants) during coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances in angioplasty techniques and the widespread use of pretreatment with two antiplatelet agents. Thus the investigators designed a study comparing safety and efficacy of standard dose heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty who are on aspirin and clopidogrel at the time of the procedure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2010

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

September 23, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 27, 2012

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

September 27, 2012

Status Verified

September 1, 2012

Enrollment Period

2.9 years

First QC Date

September 23, 2012

Last Update Submit

September 26, 2012

Conditions

Keywords

angioplastyheparintrial

Outcome Measures

Primary Outcomes (1)

  • MACE + stent thrombosis + major bleeding (TIMI definition)

    MACE (death, myocardial infarction, target vessel revascularization) + stent thrombosis + major bleeding (TIMI definition)

    30 days

Secondary Outcomes (4)

  • MACE

    30 days

  • Major Bleeding

    30 days

  • Stent thrombosis

    30 days

  • CK-MB increase

    30 days

Other Outcomes (1)

  • Major bleeding

    30 days

Study Arms (2)

Standard dose heparin

ACTIVE COMPARATOR

Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) \> 300 sec. during the procedure

Drug: Standard dose heparin

Low-dose heparin

EXPERIMENTAL

Bolus of 50 UI/Kg heparin with a target ACT during the procedure of \>200 sec.

Drug: Low-dose heparin

Interventions

Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions

Also known as: 50 UI/Kg bolus heparin
Low-dose heparin

Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.

Also known as: 100 Ui/Kg bolus heparin
Standard dose heparin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stable angina, unstable angina or Non-ST elevation myocardial infarction undergoing coronary angioplasty.
  • Mandatory pretreatment with aspirin and clopidogrel

You may not qualify if:

  • ST elevation myocardial infarction
  • Coronary interventions with rotational atherectomy
  • Coronary interventions on chronic total occlusions (CTO)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rome La Sapienza

Rome, 00161, Italy

RECRUITING

MeSH Terms

Conditions

Angina, StableAngina, UnstableNon-ST Elevated Myocardial InfarctionMyocardial Infarction

Interventions

Heparin

Condition Hierarchy (Ancestors)

Angina PectorisMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsInfarctionIschemiaPathologic ProcessesNecrosis

Intervention Hierarchy (Ancestors)

GlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • Vincenzo Pasceri, MD

    San Filippo Neri Hospital

    STUDY CHAIR
  • Francesco Pelliccia, MD

    University of Roma La Sapienza

    STUDY DIRECTOR

Central Study Contacts

Vincenzo Pasceri, MD

CONTACT

Francesco Pelliccia, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Cardiologist

Study Record Dates

First Submitted

September 23, 2012

First Posted

September 27, 2012

Study Start

January 1, 2010

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

September 27, 2012

Record last verified: 2012-09

Locations